![Figure 4. | Risk of Failure of a Clinical Drug Trial in Patients with Moderate to Severe Rheumatoid Arthritis | The Journal of Rheumatology Figure 4. | Risk of Failure of a Clinical Drug Trial in Patients with Moderate to Severe Rheumatoid Arthritis | The Journal of Rheumatology](https://www.jrheum.org/content/39/11/2066/F4.large.jpg)
Figure 4. | Risk of Failure of a Clinical Drug Trial in Patients with Moderate to Severe Rheumatoid Arthritis | The Journal of Rheumatology
![Transforming clinical trials in rheumatology: towards patient-centric precision medicine | Nature Reviews Rheumatology Transforming clinical trials in rheumatology: towards patient-centric precision medicine | Nature Reviews Rheumatology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41584-020-0491-4/MediaObjects/41584_2020_491_Fig4_HTML.png)
Transforming clinical trials in rheumatology: towards patient-centric precision medicine | Nature Reviews Rheumatology
Oncology Clinical Trials Office (OCTO) — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
![Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review](https://s3-eu-west-1.amazonaws.com/ppreviews-adisrapidplus-1069648310/25585826/preview.jpg)
Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review
![Clinical Trials in Systemic Sclerosis: Crossroads and Opportunities - Hummers - Arthritis & Rheumatology - Wiley Online Library Clinical Trials in Systemic Sclerosis: Crossroads and Opportunities - Hummers - Arthritis & Rheumatology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/f32a1338-2211-4381-934e-978138528992/art.42514.fp.png)
Clinical Trials in Systemic Sclerosis: Crossroads and Opportunities - Hummers - Arthritis & Rheumatology - Wiley Online Library
![PDF] Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials II: the Rheumatology Common Toxicity Criteria v.2.0 | Semantic Scholar PDF] Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials II: the Rheumatology Common Toxicity Criteria v.2.0 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/90a1a83c8567389252da526a1a9957f683ce1465/3-Table1-1.png)
PDF] Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials II: the Rheumatology Common Toxicity Criteria v.2.0 | Semantic Scholar
![Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti- rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial - The Lancet Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti- rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/2119370149/2092874011/gr1.gif)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti- rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial - The Lancet
![Changes in Outcome Measures in Rheumatology Clinical Trials (OMERACT)... | Download Scientific Diagram Changes in Outcome Measures in Rheumatology Clinical Trials (OMERACT)... | Download Scientific Diagram](https://www.researchgate.net/publication/269712823/figure/fig1/AS:267622809862159@1440817658552/Figure2-Changes-in-Outcome-Measures-in-Rheumatology-Clinical-Trials-OMERACT-rheumatoid.png)